The North American Malignant Hyperthermia Registry

### Report of Malignant Hyperthermia Research Subject

# **Already Known As**

## Malignant Hyperthermia Susceptible

("AKA Report")

### **INSTRUCTIONS:**

This form is to be filled out by the person to be registered and their anesthesiologist/health care provider.

- 1. To register your name with the North American Malignant Hyperthermia Registry, sign the consent form for release of information by you and your physician to the North American Malignant Hyperthermia Registry and for release of information by the North American Malignant Hyperthermia Registry to your future physicians. If both parents of a child who experienced an episode of MH wish to be registered, then separate consent forms must be signed for each parent.
- 2. You can answer all questions except possibly 17-20 and 29-40. You may need to consult with your anesthesiologist or other physician responsible for diagnosing you as MH susceptible for assistance.
- 3. Send this AKA report to the anesthesiologist or other physician responsible for diagnosing you as MH susceptible. Please ask this physician to complete the rest of this form (questions 17-20 and 29-40). If this physician is not available, fill out as much of the form as you can.
- 4. Send this form and all signed consent forms directly to the North American MH Registry (address at bottom of this page). You will need to call the NAMHR office at (888) 274-7899 and speak to Dr. Gravenstein or one of the registry staff to confirm your consent by conversation over the phone. Each person who signed a consent form will need to call the North American MH Registry to confirm that consent by conversation on the telephone as well.
- 5. Information sent to the North American MH Registry (NAMHR) will remain confidential. Patient specific information will only be accessible by people specifically designated by the research subject.

### **Return original completed form to:**

The North American Malignant Hyperthermia Registry University of Florida Department of Anesthesiology 1600 SW Archer Road, PO Box 100254 Gainesville, FL 32610-0254 1-888-274-7899

## **AKA MH REPORT**

(Version 7.5 May 2014)

## **PATIENT IDENTIFICATION** (to be completed by the research subject or subject's guardian)

last	first	middle
Previous name		
last	first	middle
Maiden name:last		
Address		
street address		
city	state/province	zip/postal code
country	_	
Phone number		
()	home work	
E-mail address		

8.	Weight at the time of	your MH episode:		
	kilograms (	OR lbs		
9.	Height at the time of	your MH episode:		
	cm OR f	t inches		
10.	Date of subject's birth			
- ;	year month	day		
11.	<ul><li>( ) Caucasian</li><li>( ) Hispanic</li><li>( ) African-Ame</li><li>( ) Native Ame</li><li>( ) Hawaiian or</li></ul>	mographic purposes only)  ( ) ( ) erican ( )	African East Asian South Asian Middle Eastern	
12.				
c				
13.	Does the subject have	minor children or siblidian consent to the child	ngs under the age of d being in the Regis	
<b>a.</b> 1	name 			
	last	first		middle
	Date of birth			

<i>check one</i> ()child		
( ) child		
( ) sibling		
name		
last	first	middle
Date of birth		
rear month day		
rear month day		
s this the child or the sibling of th	ne research subject?	
check one		
( ) child ( ) sibling		
( ) storing		
name		
last	first	middle
Date of birth		
rear month day		
rear month day		
Is this the child or the sibling of	f the research subject?	
check one		
( ) child		
( ) sibling		
name		
last	first	middle
Date of birth		
\\		
rear month day		

<b>.</b>	name		
	last	first	middle
	Date of birth		
	\\\	_	
	year month day		
	Is this the child or the sibling	g of the research subject?	,
	check one	J	
	( ) child		
	( ) sibling		
	Has consent been obtained to	o enter the names of child	dren or siblings ages 6 through 17, or
	ages 18 and over, of the inde	ex research subject into the	ne Registry?
	cck your local/state regulations regulatio	( ) no duals for whom consent h	as been obtained
	last	first	middle
	Date of birth	_	
	year month day	a of the index research sy	shipat?
	Is this the child or the sibling check one	g of the index research su	ibject?
	( ) child		
	( ) sibling		
	( ) storing		
	name		
	last	first	middle
	Date of birth		
	Date of birth  year month day	-	

15 (	his the child or the sibling of the check one  ( ) child ( ) sibling	e muex research subject:	
c.	name		
	last	first	middle
	Date of birth  year month day  Is this the child or the sibling	—  ng of the index research sub	oject?
	check one ( ) child ( ) sibling		
d.	name		
	last	first	middle
	Date of birth  year month day  Is this the child or the sibling  check one  ( ) child  ( ) sibling	— ng of the index research sub	oject?
5.	Has consent been obtained to index research subject is your check one ( ) yes  If yes, complete below	child, your information go ( ) no	ents of the research subject? If the es in this section.
EN TH	TER	ceased, the following data	PARENT FOR WHOM YOU may be entered regardless of
	Date of mother's birth  year month day	first	middle

### b. Father of the index research subject

last first middle

Date of father's birth

year month day

### 16. Family History Table

Key to Family History table (below)

#### Relationship to Subject

- a. child
- b. grandchild
- c. brother/sister
- d. half-sibling results
- e. niece/nephew
- f. mother
- g. maternal grandparent
- h. maternal aunt/uncle
- j. maternal first cousin
- k. maternal second cousin
- m. maternal other
- n. father
- o. paternal grandparent Syndrome)
- p. paternal aunt/uncle
- q. paternal first cousin
- r. paternal second cousin
- s. paternal other
- t. relative by marriage
- u. other blood relative

#### **Known Medical Problems**

- 1. fatal MH
- 2. survived fulminant MH event
- 3. possible MH event
- 4. MH family history (only for those relatives with CHCT
- 5. perioperative death not thought to be MH
- 6. perioperative death etiology undetermined
- 7. S.I.D.S. or cot death
- 8. Sudden death unknown cause, age 1.5 to 45 yrs
- 9. heat stroke
- 10. neurolept malignant syndrome
- 11. myopathy
- 12. idiopathic creatine kinase elevation
- 13. CFIDS (Chronic Fatigue and Immune Dysfunction
- 14. muscle pain, weakness or fever with exercise
- 15. episodic dark urine and muscle pain
- 16. none of the above
- 17. unknown

Relative's <u>Initials</u>	Number Leave blank if relative not registered. Insert "?" if relative registered but number not known	Relationship to Subject Select one letter from left-hand column above.	<u>Sex</u> M=Male F=Female	Medical Problems Select one or more numbers from right-hand column above.	CHCT Test Result Write "pos", "neg", "equiv", "unknown" or "not performed", "other"	Genetic Result Specify familial mutation or "neg", "not performed", or "other"
0	HAN'S IDENTIFIC Optional-for Registry nesthesiologist's or o	use only		ed by the physi	cian)	Pag
	last		first		middle	_
18. H	ospital name					
19. H	ospital Address					
str	reet address					
	city		state/provi	nce	zip/postal cod	e e
20 P	country		,			

# **FAMILY HISTORY**

21.	Family history is positive for:
	Check all applicable
	( ) malignant hyperthermia
	( ) masseter spasm
	( ) intraoperative death <u>not</u> thought to be MH
	( ) sudden infant death syndrome or cot death
	( ) sudden death from unknown cause at < 45 year >1.5 years
	( ) heatstroke
	( ) neurolept malignant syndrome
	( ) intolerance to heat
	( ) chronic muscle pain
	( ) frequent muscle cramps
	( ) chronic muscle weakness
	( ) exercise intolerance due to muscle pain, weakness or fever
	( ) episodes of dark urine and muscle pain
	( ) myopathies specify type; write unknown if not known:
	( ) idiopathic creatine kinase elevation
	( ) diabetes
	( ) none of the above
	( ) unknown
	( ) other ( <i>specify</i> )
<u>MED</u>	OICAL HISTORY
22.	Does the subject have any of the following?
<i>LL</i> .	check all applicable
	( ) muscle weakness interferes with daily activity at least once/week
	( ) muscle cramps or pain interfere with daily activity at least once/week
	( ) cola colored urine
	( ) heat stroke or heat prostration
	( ) oral (or rectal/axillary equivalent) fever>38.6°C or 101.4 ° F at least 6 times/year without medical cause
	( ) recent generalized infection
	If there was infection, how long ago was it? (days)
	( ) recent use of cholesterol lowering drugs
	If so, which drug, and when was it last ingested? (days)
	( ) a regular regimen of physical activity?
	If so, when was the last work-out? (days)
	( ) ingestion of any medicine to improve muscular performance
	( ) intolerance to heat
	( ) exercise intolerance due to muscle pain, weakness or fever
	( ) diabetes
	( ) none of the above

	( ) unknown
	( ) other (specify):
23.	Has the subject ever had physical findings of:
	check all applicable
	( ) increased muscle tone
	( ) decreased muscle tone
	( ) generalized muscle weakness
	( ) myopathy specify type; write unknown if not known:
	( ) ptosis
	( ) strabismus
	( ) hiatal hernia
	( ) inguinal hernia
	( ) umbilical hernia
	( ) undescended testes
	( ) clubbed foot
	( ) joint hypermobility
	( ) kyphoscoliosis (moderate or severe; curve >45°)
	( ) pectus carinatum
	( ) winged scapulae
	( ) skeletal fractures (more than 2)
	( ) gallstones
	( ) kidney stones
	( ) laryngeal papillomas
	( ) other (specify):
	( ) none of the above
	( ) unknown
ANE	STHETIC HISTORY
24.	How many times was this subject anesthetized prior to this evaluation?
	— — ( ) unknown
	Skip to question 28 if the response is zero or unknown.
	skip to question 20 if the response is zero or unknown.
25.	How many were general anesthetics?
	— — ( ) unknown
26.	Indicate the number of anesthetics with the following agents:
	volatile agents without succinylcholine
	volatile agents with succinylcholine
	succinylcholine without other known triggering agents

27.	<ul> <li>check all applicable</li> <li>( ) clear-cut clinical MH episode(s)</li> <li>( ) possible MH (not clear-cut MH)</li> <li>( ) masseter muscle rigidity only</li> <li>( ) delayed awakening from general anesthesia</li> <li>( ) positive caffeine halothane contracture test</li> <li>( ) positive calcium uptake test (performed in Boston)</li> <li>( ) other (specify):</li></ul>		
	<ul><li>( ) none of the above</li><li>( ) unknown</li></ul>		
28a ans	wer for anesthetic most suspect for MH	e	
	year month day		
28b	Year of most recent anesthetic (excluding	ng present episode).	
	yea ( ) unknown	ur	
29.	Pre-medication and anesthetic agents uti check all applicable	ilized during possible /clear cut MH:	
(	) sodium citrated citric acid (Bicitra)	( ) ketorolac (Toradol)	
(	) cimetidine (Tagamet)	( ) acetaminophen (Tylenol)	
(	) famotidine (Pepcid)		
(	) lansoprazole (Prevacid)	( ) diazepam (Valium)	
(	) ranitidine (Zantac)	( ) lorazepam (Ativan)	
		( ) midazolam (Versed)	
(	) metoclopramide (Reglan)		
(	) omeprazole (Prilosec)	( ) etomidate (Amidate)	
		( ) ketamine (Ketalar)	
(	) atropine	( ) propofol (Diprivan)	
(	) glycopyrrolate (Robinul)		
(	) scopolamine (Hyoscine)	( ) alfentanil (Alfenta)	
		( ) fentanyl (Sublimaze)	
(	) dolasetron (Anzemet)	( ) fentanyl and droperidol	
(	) droperidol (Inapsine)	(Innovar)	
(	) hydroxyzine (Vistaril)	( ) meperidine (Demerol)	
(	) ondansetron (Zofran)	( ) morphine	
(	) promethazine (Phenergan)	( ) remifentanyl (Ultiva)	
(	) diphenhydramine (Benedryl)	( ) sufentanil (Sufenta)	
(	) clonidine (Duraclon)	( ) hydromorphone (Dilaudid)	

(	) unknown	(	) neostigmine (Prostigmin)
(	) <b>NO</b> potent volatile anesthetics	(	) physostigmine (Antilirium)
(	) sevoflurane (Ultane)	(	) pyridostigmine (Mestinon)
(	) desflurane (Suprane)		
(	) isoflurane (Forane)	(	) bupivacaine (Marcaine)
(	) nitrous oxide	(	) levo-bupivacaine
		(	) choroprocaine (Nesacaine)
(	) nalbuphine (Nubain)	(	) cocaine
(	) naloxone (Narcan)	(	) etidocaine (Duranest)
		(	) lidocaine (Xylocaine)
(	) atracurium (Tracrium)	(	) mepivacaine (Carbocaine)
(	) cisatracurium (Nimbex)	(	) prilocaine (Citanest)
(	) rocuronium (Zemuron)	(	) procaine (Novocain)
(	) vecuronium (Norcuron)	(	) ropivacaine (Naropin)
(	) pancuronium (Pavulon)	(	) tetracaine (Pontocaine)
(	) other NMB		
(	) IM succinylcholine (Anectine)	(	) epinephrine
(	) IV succinylcholine (Anectine)	(	) ephedrine
(	) <b>NO</b> succinylcholine	(	) neosynephrine
(	) edrophonium (Tensilon)		
(	) other ( <i>specify</i> ):		

30. Signs and abnormal findings during possible or fulminant MH Abnormal signs noted by the attending anesthesiologist or other physician. RANK in order of appearance. NUMBER do not check. WRITE ZERO if sign did not occur. (a number may be used more than once if signs were noted simultaneously) \_\_\_\_ masseter spasm: mouth cannot be fully opened, but direct laryngoscopy is possible masseter spasm: jaw clamped shut, intubation by direct visualization impossible \_\_\_\_ generalized muscular rigidity \_\_\_\_ cola colored urine \_\_\_\_ tachypnea \_\_\_\_ hypercarbia \_\_\_\_ cyanosis \_\_\_\_ sinus tachycardia \_\_\_\_ ventricular tachycardia \_\_\_\_ ventricular fibrillation \_\_\_\_ elevated temperature \_\_\_\_ rapidly increasing temperature \_\_\_\_ sweating \_\_\_\_ excessive bleeding \_\_\_\_ skin mottling \_\_\_\_ hypertension > 20% baseline \_\_\_\_ other (*specify*): \_\_ \_\_\_\_ none of the above 31. Abnormal metabolic values during possible or fulminant MH Most abnormal arterial blood gas after MH was suspected: FiO<sub>2</sub> pН  $PCO_2$ \_\_\_ \_\_  $PO_2$ BE (mEq/L) (specify  $\pm$ ) Bicarbonate (mEq/L) time (hours after induction) peak lactic acid mmol/L peak K<sup>+</sup> \_\_\_ \_\_.\_\_ mEq/L or mmol/L

	peak post-op creatine kinase*	first creatine kinase*	last creatine kinase*
	_ hours after inductionl		hrs after induction are 0, 6, 12, 24 hours after adverse
	tion)	ine kinase uetermination	are 0, 0, 12, 24 hours aren auverse
32.	( ) Hyperventilation with ( ) Dantrolene (type)	tial dose (mg) me of first dose (hours after tal dose (mg) me of last dose (Hours after tal dose)	· induction)
33.	( ) unknown  Were any problems noted with check one		ration?
	If no, please skip to q	uestion 35	

34.	What were the observed dantrolene complications?
	check all applicable
	( ) phlebitis
	( ) excessive secretions
	( ) gastrointestinal upset
	( ) hyperkalemia
	( ) muscle weakness
	( ) respiratory failure
	( ) other specify:
<u>DNA</u>	TESTING (to be completed by the physician)
35.	Was a genetic test performed?
	check one
( ) y	es ( ) no
36.	Where was the genetic test done?
36a.	Is a sample of the DNA stored in the lab?
	( ) yes
	( ) no
27	
37.	When was the genetic test done?
	<del></del>
38.	Which of the RYR1 exons were examined?
39.	Was any mutation associated with MH or central core disease present?
	check one ( ) yes ( ) no If yes,
specif	fy:
10.	William and the common and the control of the contr
40a.	Were any other sequence variants identified?
an '	check one ( ) yes ( ) no If yes,
specit	V.

40b. <i>check</i>	Did the subject survive the initial reaction?
( ) y	
40b.	Did the subject survive any subsequent reaction (recrudescence) and recovery? check one
( ) y	es ( ) unknown because of transfer of case during treatment ( ) no
MH I	DIAGNOSTIC MUSCLE BIOPSY
Answ	er for caffeine halothane contracture test or European IVCT test only. These tests are only done at Biopsy centers, and are different from regular pathology biopsies.
41.	Date of diagnostic muscle biopsy
	year month day
42.	Results
	check one
	( ) positive—MH susceptible
	( ) negative—not susceptible to MH
	( ) equivocal—MH susceptibility indeterminate
43.	Center which performed MH Biopsy (Caffeine Halothane Contracture Test)
	check one
	( ) Children's Hospital of Oklahoma
	( ) Cleveland Clinic
	( ) Hahnemann University
	( ) Thomas Jefferson University
	( ) Loyola University
	( ) Northwestern University
	( ) Mayo Clinic
	( ) Ottawa Hospital- Civic Campus
	( ) Presbyterian University Hospital (Pittsburgh)
	( ) Toronto General Hospital
	( ) UC-Davis
	( ) UCLA
	( ) Uniformed Services University
	( ) University of Calgary
	( ) University of Florida
	( ) University of Iowa

	( ) University of Manitoba
	( ) University of Massachusetts
	( ) University of Nebraska
	( ) University of South Florida
	( ) University of Texas-Houston
	( ) University of Texas Medical Branch
	( ) University of Washington
	( ) University of Wisconsin
	( ) Wake Forest University
	( ) other ( <i>specify</i> ):
	(Signature of subject submitting this report)
	(Signature of subject submitting this report)
	year month day
CON	MMENTS ON SUBJECT
<i>Optio</i>	onal — — — — — — — — — — — — — — — — — — —